NCT05322473Phase 2Completed

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Study sponsor: MoonLake Immunotherapeutics AG

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-05-09Actual
Enrollment · participants234Actual
Source updated2026-09-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Hidradenitis Suppurativa Clinical Response 75. After: Measure: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 12.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview